Conversely, adrenergic agonists increase AMPK activity in cardiac hypertrophy [74] and increased phosphorylation of AMPK at Thr172 is associated with anti-hypertrophic effects [73]. Here, PRKAA2 is linked to cardiac hypertrophy.